Clinical Trial Update: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in advanced HER-2 negative stomach/g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Neoplasms
• Gastroesophageal Junction Cancer
• Stomach Neoplasms

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Stomach Neoplasms | Phase 3 | Status: UNKNOWN